Sleep-inducing factors

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 4, 2009, Pages 235-244

  García García, Fabio ^a   Acosta Peña, Eva ^a   Venebra Muñoz, Arturo ^a   Murillo Rodríguez, Eric ^b  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b Universidad del Mayab   (Mexico)

Author keywords

Cannabinoids; Humoral sleep regulation; Purine; Stress

Indexed keywords

ADENOSINE; ANANDAMIDE; BETA ENDORPHIN; CHOLECYSTOKININ OCTAPEPTIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN[18-39]; CYTOKINE; DELTA SLEEP INDUCING PEPTIDE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYPNOTOXIN; INSULIN; LIPID; MURAMYL PEPTIDE; NEUROPEPTIDE; NEUROTRANSMITTER; OLEAMIDE; PROLACTIN; UNCLASSIFIED DRUG; URIDINE; VASOACTIVE INTESTINAL POLYPEPTIDE; AMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID;

BRAIN REGION; BRAIN STEM; GRAY MATTER; HUMAN; HYPOTHALAMUS; LOCUS CERULEUS; NERVE PROJECTION; NEUROMODULATION; NONHUMAN; NONREM SLEEP; REGULATORY MECHANISM; REM SLEEP; REVIEW; SLEEP; SLEEP DEPRIVATION; SLEEP WAKING CYCLE; STRESS; SUPRACHIASMATIC NUCLEUS; THALAMUS MIDLINE NUCLEUS; WAKEFULNESS; ANIMAL; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ADENOSINE; ANIMALS; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; HUMANS; POLYUNSATURATED ALKAMIDES; PROLACTIN; SLEEP; SLEEP, REM; STRESS, PHYSIOLOGICAL; VASOACTIVE INTESTINAL PEPTIDE;

EID: 70350441463     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709788921672     Document Type: Review

References (131)

1. Borbely, AA.; Tobler, I. The search for an endogenous sleep substance. TIPS., 1984, 1, 356-358.
2. Jouvet, M. Neuromediateurs et facteurs hypnogenes. Rev. Neurol. (Paris), 1984, 140(6-7), 389-400.
3. Piaget, J. Henri Piéron: 1881-1964. Am. J. Psychol., 1966, 79, 147-150.
4. Kleitman, N. In Deprivation of Sleep; Kleitman, N., Ed.; Midway reprint University of Chicago Press: USA, 1987, pp. 215-229.
5. Said, S.I.; Mut, V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature, 1970, 225(5235), 863-864.
6. Delgado, M.; Abad, C.; Martinez, C.; Receta, J.; Gomariz, R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med., 2001, 7(5), 563-568.
7. Delgado, M.; Ganea, D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J., 2003, 17(13), 1922-1924.
8. Henning, R.J.; Sawmiller, D.R. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res., 2001, 49(1), 27-37.
9. Usdin, T.B.; Bonner, T.I.; Mezey, E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology, 1994, 135(6), 2662-80.
10. Wei, Y.; Mojsov, S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J. Neuroendocrinol., 1996, 8(11), 811-817.
11. Riou, F.; Cespuglio, R.; Jouvet, M. Hypnogenic properties of the vasoactive intestinal polypeptide in rats. C. R. Seances Acad. Sci. III, 1981, 293(12), 679-682.
12. Drucker-Colín, R.; Bernal-Pedraza, J.; Fernandez-Cancino, F.; Oksenberg, A. Is vasoactive intestinal polypeptide (VIP) a sleep factor? Peptides, 1984, 5(4), 837-840.
13. Drucker-Colín, R.; Aguilar-Roblero, R.; Arankowsky-Sandoval, G. Sleep factors released from brain of unrestrained cats: a critical appraisal. Ann. N.Y. Acad. Sci., 1986, 473, 449-460.
14. Obál, F.Jr. Effects of peptides (DSIP, DSIP analogues, VIP, GRF and CCK) on sleep in the rat. Clin. Neuropharmacol., 1986, 9(4), 459-461.
15. Obál, F.Jr.; Opp, M.; Cady, A.B.; Johannsen, L.; Krueger, J.M. Prolactin, vasoactive intestinal peptide, and peptide histidine methionine elicit selective increases in REM sleep in rabbits. Brain Res., 1989, 490(2), 292-300.
16. Obál, F.Jr.; Sary, G.; Alfoldi, P.; Rubicsek, G.; Obal, F. Vasoactive intestinal polypeptide promotes sleep without effects on brain temperature in rats at night. Neurosci. Lett., 1986, 64(2), 236-240.
17. Prospero-García, O.; Morales, M.; Arankowsky-Sandoval, G.; Drucker-Colín, R. Vasoactive intestinal polypeptide (VIP) and cerebrospinal fluid (CSF) of sleep-deprived cats restores REM sleep in insomniac recipients. Brain Res., 1986, 385(1), 169-173.
18. Drucker-Colín, R.; Prospero-García, O.; Perez-Montfort, R.; Pacheco-Cano, M.T. Vasoactive intestinal polypeptide (VIP) a sleep factor? Ann. N.Y. Acad. Sci., 1988, 527, 627-630.
19. Pacheco-Cano, M.T.; García-Hernandez, F.; Prospero-García, O.; Drucker-Colín, R. Vasoactive intestinal polypeptide induces REM recovery in insomniac forebrain lesioned cats. Sleep, 1990, 13(4), 297-303.
20. Morin, A.J.; Denoroy, L.; Jouvet, M. Effect of paradoxical sleep deprivation on vasoactive intestinal peptide-like immunoreactivity in discrete brain areas and anterior pituitary of the rat. Brain Res. Bull., 1992, 28(5), 655-661.
21. Morin, A.J.; Denoroy, L.; Jouvet, M. Daily variations in concentration of vasoactive intestinal peptide immunoreactivity in hypothalamic nuclei of rats rendered diurnal by restricted-schedule feeding. Neurosci. Lett., 1993, 152(1-2), 121-124.
22. Schilling, J.; Nurnberger, F. Dynamic changes in the immunoreactivity of neuropeptide systems of the suprachiasmatic nuclei in golden hamsters during the sleep-wake cycle. Cell Tissue Res., 1998, 294(2), 233-241.
23. Jimenez-Anguiano, A.; Baez-Saldana, A.; Drucker-Colín, R. Cerebrospinal fluid (CSF) extracted immediately after REM sleep deprivation prevents REM rebound and contains vasoactive intestinal peptide (VIP). Brain Res., 1993, 631(2), 345-348.
24. Jimenez-Anguiano, A.; García-García, F.; Mendoza-Ramirez, J.L.; Duran- Vazquez, A.; Drucker-Colín, R. Brain distribution of vasoactive intestinal peptide receptors following REM sleep deprivation. Brain Res., 1996, 728(1), 37-46.
25. Bourgin, P.; Lebrand, C.; Escourrou, P.; Gaultier, C.; Franc, B.; Hamon, M.; Adrien, J. Vasoactive intestinal polypeptide microinjections into the oral pontine tegmentum enhance rapid eye movement sleep in the rat. Neuroscience, 1997, 77(2), 351-360.
26. Whittaker, V.P. Vasoactive intestinal polypeptide (VIP) as a cholinergic co-transmitter: some recent results. Cell Biol. Int. Rep., 1989, 13(12), 1039-51.
27. Magistretti, P.J. VIP neurons in the cerebral cortex. Trends Pharmacol. Sci., 1990, 11(6), 250-254.
28. Bourgin, P.; Ahnaou, A.; Laporte, A.M.; Hamon, M.; Adrien, J. Rapid eye movement sleep induction by vasoactive intestinal peptide infused into the oral pontine tegmentum of the rat may involve muscarinic receptors. Neuroscience, 1999, 89(1), 291-302.
29. Kohlmeier, K.A.; Reiner, P.B. Vasoactive intestinal polypeptide excites medial pontine reticular formation neurons in the brainstem rapid eye movement sleep-induction zone. J. Neurosci., 1999, 19(10), 4073-4081.
30. Baghdoyan, H.A.; Spotts, J.L.; Snyder, S.G. Simultaneous pontine and basal forebrain microinjections of carbachol suppress REM sleep. J. Neurosci., 1993, 13(1), 229-242.
31. Prospero-García, O.; Jimenez-Anguiano, A.; Drucker-Colín, R. The combination of VIP and atropine induces REM sleep in cats rendered insomniac by PCPA. Neuropsychopharmacology, 1993, 8(4), 387-390.
32. Obál, F.Jr.; Payne, L.; Kacsoh, B.; Opp, M.; Kapas, L.; Grosvenor, C.E.; Krueger, J.M. Involvement of prolactin in the REM sleep-promoting activity of systemic vasoactive intestinal peptide (VIP). Brain Res., 1994, 645(1-2), 143-149.
33. Bredow, S.; Kacsoh, B.; Obál, F. Jr.; Fang, J.; Krueger, J.M. Increase of prolactin mRNA in the rat hypothalamus after intracerebroventricular injection of VIP or PACAP. Brain Res., 1994, 660(2), 301-308.
34. Jouvet, M.; Buda, C.; Cespuglio, R.; Chastrette, N.; Denoyer, M.; Sallanon, M.; Sastre, J.P. Hypnogenic affects of some hypothalamo-pituitary peptides. Clin. Neuropharmacol., 1986, 9, 465-467.
35. Valatx, J.L.; Jouvet, M. Circadian rhythms of slow-wave sleep and paradoxical sleep are in opposite phase in genetically hypoprolactinemic rats. C. R. Acad. Sci. III, 1988, 307(17), 789-794.
36. Roky, R.; Valatx, J.L.; Jouvet, M. Effect of prolactin on the sleepwake cycle in the rat. Neurosci. Lett., 1993, 156(1-2), 117-120.
37. Zhang, S.Q.; Kimura, M.; Inoue, S. Effects of prolactin on sleep in cyclic rats. Psychiatry. Clin. Neurosci., 1999, 53(2), 101-103.
38. Obál, F.Jr.; Kacsoh, B.; Alfoldi, P.; Payne, L.; Markovic, O.; Grosvenor, C.; Krueger, J.M. Antiserum to prolactin decreases rapid eye movement sleep (REM sleep) in the male rat. Physiol. Behav., 1992, 52(6), 1063-1068.
39. Roky, R.; Valatx, J.L.; Paut-Pagano, L.; Jouvet, M. Hypothalamic injection of prolactin or its antibody alters the rat sleep-wake cycle. Physiol. Behav., 1994, 55(6), 1015-1019.
40. Zhang, S.Q.; Inoue, S.; Kimura, M. Sleep-promoting activity of prolactin-releasing peptide (PrRP) in the rat. Neuroreport, 2001, 12(15), 3173-3176.
41. Zhang, S.Q.; Kimura, M.; Inoue, S. Effects of prolactin-releasing peptide (PrRP) on sleep regulation in rats. Psychiatry Clin. Neurosci., 2000, 54(3), 262-264.
42. Takahashi, K.; Koyama, Y.; Kayama, Y.; Yamamoto, M. The effects of prolactin on the mesopontine tegmental neurons. Psychiatry Clin. Neurosci., 2000, 54(3), 257-258.
43. Siaud, P.; Manzoni, O.; Balmefrezol, M.; Barbanel, G.; Assenmacher, I.; Alonso, G. The organization of prolactin-like-immunoreactive neurons in the rat central nervous system. Light- and electron-microscopic immunocytochemical studies. Cell Tissue Res., 1989, 255(1), 107-115.
44. Roky, R.; Paut-Pagano, L.; Goffin, V.; Kitahama, K.; Valatx, J.L.; Kelly, P.A.; Jouvet, M. Distribution of prolactin receptors in the rat forebrain. Immunohistochemical study. Neuroendocrinology, 1996, 63(5), 422-429.
45. Sanford, L.D.; Nassar, P.; Ross, R.J.; Schulkin, J.; Morrison, A.R. Prolactin microinjections into the amygdalar central nucleus lead to decreased NREM sleep. Sleep Res. Online, 1998, 1(3), 109-113.
46. Calvo, J.M.; Simon-Arceo, K.; Fernandez-Mas, R. Prolonged enhancement of REM sleep produced by carbachol microinjection into the amygdale. Neuroreport, 1996, 7(2), 577-580.
47. Paut-Pagano, L.; Roky, R.; Valatx, J.L.; Kitahama, K.; Jouvet, M. Anatomical distribution of prolactin-like immunoreactivity in the rat brain. Neuroendocrinology, 1993, 58(6), 682-695.
48. Bispink, G.; Zimmermann, R.; Weise, H.C.; Leidenberger, F. Influence of melatonin on the sleep-independent component of prolactin secretion. J. Pineal Res., 1990, 8(2), 97-106.
49. Tobler, I.; Jaggi, K.; Borbely, A.A. Effects of melatonin and the melatonin receptor agonist S-20098 on the vigilance states, EEG spectra, and cortical temperature in the rat. J. Pineal Res., 1994, 16(1), 26-32.
50. Roky, R.; Obál, F.Jr.; Valatx, J.L.; Bredow, S.; Fang, J.; Pagano, L.P.; Krueger, J.M. Prolactin and rapid eye movement sleep regulation. Sleep, 1995, 18(7), 536-542.
51. Spiegel, K.; Luthringer, R.; Follenius, M.; Schaltenbrand, N.; Macher, J.P.; Muzet, A.; Brandenberger, G. Temporal relationship between prolactin secretion and slow-wave electroencephalic activity during sleep. Sleep, 1995, 18(7), 543-548.
52. Sassin, J.F.; Frantz, A.G.; Weitzman, E.D.; Kapen, S. Human prolactin: 24-hour pattern with increased release during sleep. Science, 1972, 177(55), 1205-1207.
53. Sassin, J.F.; Frantz, A.G.; Kapen, S.; Weitzman, E.D. The nocturnal rise of human prolactin is dependent on sleep. J. Clin. Endocrinol. Metab., 1973, 37(3), 436-440.
54. Van Cauter, E.; L'Hermite, M.; Copinschi, G.; Refetoff, S.; Desir, D.; Robyn, C. Quantitative analysis of spontaneous variations of plasma prolactin in normal man. Am. J. Physiol., 1981, 241(5), E355-363.
55. Linkowski, P.; Spiegel, K.; Kerkhofs, M.; L'Hermite-Balériaux, M.; Van Onderbergen, A.; Leproult, R.; Mendlewicz, J.; Van Cauter, E. Genetic and environmental influences on prolactin secretion during wake and during sleep. Am. J. Physiol., 1998, 274(5 Pt 1), E909-919.
56. Appelberg, B.; Katila, H.; Rimón, R. REM sleep and prolactin in patients with non-affective psychoses. Psychoneuroendocrinology, 2002, 27(6), 661-669.
57. Spiegel, K.; Follenius, M.; Simon, C.; Saini, J.; Ehrhart, J.; Brandenberger, G. Prolactin secretion and sleep. Sleep, 1994, 17(1), 20-27.
58. García-García, F.; Beltrán-Parrazal, L.; Jiménez-Anguiano, A.; Vega-González, A.; Drucker-Colín, R. Manipulations during forced wakefulness have differential impact on sleep architecture, EEG power spectrum, and Fos induction. Brain Res. Bull., 1998, 47(4), 317-324.
59. Palma, B.D.; Suchecki, D.; Tufik, S. Differential effects of acute cold and footshock on the sleep of rats. Brain Res., 2000, 861(1), 97-104.
60. Rampin, C.; Cespuglio, R.; Chastrette, N.; Jouvet, M. Immobilisation stress induces a paradoxical sleep rebound in rat. Neurosci. Lett., 1991, 126(2), 113-118.
61. Gonzalez, M.M.; Debilly, G.; Valatx, J.L.; Jouvet, M. Sleep increase after immobilization stress: role of the noradrenergic locus coeruleus system in the rat. Neurosci. Lett., 1995, 202(1-2), 5-8.
62. Bouyer, J.J.; Deminiére, J.M.; Mayo, W.; Le Moal, M. Inter-individual differences in the effects of acute stress on the sleep-wakefulness cycle in the rat. Neurosci. Lett., 1997, 225(3), 193-196.
63. Gala, R.R. The physiology and mechanisms of the stress-induced changes in prolactin secretion in the rat. Life Sci., 1990, 46(20), 1407-1420.
64. Bodosi, B.; Obál, F.Jr.; Gardi, J.; Komlódi, J.; Fang, J.; Krueger, J.M. An ether stressor increases REM sleep in rats: possible role of prolactin. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(5): R1590-1598.
65. Meerlo, P.; Easton, A.; Bergmann, B.M.; Turek, F.W. Restraint increases prolactin and REM sleep in C57BL/6J mice but not in BALB/cJ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281(3), R846-854.
66. Ogawa, T.; Kiryu-Seo, S.; Tanaka, M.; Konishi, H.; Iwata, N.; Saido, T.; Watanabe, Y.; Kiyama, H. Altered expression of neprilysin family members in the pituitary gland of sleep-disturbed rats, an animal model of severe fatigue. J. Neurochem., 2005, 95(4), 1156-1166.
67. Menzaghi, F.; Heinrichs, S.C.; Pich, E.M.; Weiss, F.; Koob, G.F. The role of limbic and hypothalamic corticotropin-releasing factor in behavioral responses to stress. Ann. N. Y. Acad. Sci., 1993, 697, 142-154.
68. Morel, G.; Enjalbert, A.; Proulx, L.; Pelletier, G.; Barden, N.; Grossard, F.; Dubois, P.M. Effect of corticotropin-releasing factor on the release and synthesis of prolactin. Neuroendocrinology, 1989, 49(6), 669-675.
69. González, M.M.; Valatx, J.L. Effect of intracerebroventricular administration of alpha-helical CRH (9-41) on the sleep/waking cycle in rats under normal conditions or after subjection to an acute stressful stimulus. J. Sleep Res., 1997, 6(3), 164-170.
70. García-García, F. La vigilia como regulador del sueño: estudio sobre los péptidos involucrados. Doctoral Thesis. UNAM. México, 2000.
71. Maruyama, M.; Matsumoto, H.; Fujiwara, K.; Noguchi, J.; Kitada, C.; Fujino, M.; Inoue, K. Prolactin-releasing peptide as a novel stress mediator in the central nervous system. Endocrinology, 2001, 142(5), 2032-2038.
72. Matsumoto, H.; Maruyama, M.; Noguchi, J.; Horikoshi, Y.; Fujiwara, K.; Kitada, C.; Hinuma, S.; Onda, H.; Nishimura, O.; Inoue, K.; Fujino, M. Stimulation of corticotropin-releasing hormone-mediated adrenocorticotropin secretion by central administration of prolactin-releasing peptide in rats. Neurosci. Lett., 2000, 285(3), 234-238.
73. Morales, T.; Hinuma, S.; Sawchenko, P.E. Prolactin-releasing peptide is expressed in afferents to the endocrine hypothalamus, but not in neurosecretory neurones. J. Neuroendocrinol., 2000, 12(2), 131-140.
74. Bohnet, S.G.; Traynor, T.R.; Majde, J.A.; Kacsoh, B.; Krueger, J.M. Mice deficient in the interferon type I receptor have reduced REM sleep and altered hypothalamic hypocretin, prolactin and 2',5'-oligoadenylate synthetase expression. Brain Res., 2004, 1027(1-2), 117-125.
75. Obál, F.Jr.; Garcia-Garcia, F.; Kacsóh, B.; Taishi, P.; Bohnet, S.; Horseman, N.D.; Krueger, J.M. Rapid eye movement sleep is reduced in prolactin-deficient mice. J. Neurosci., 2005, 25(44), 10282-10289.
76. Feldberg, W.; Sherwood, S.L. Injections of drugs into the lateral ventricle of the cat. J. Physiol., 1954, 123, 148-167.
77. Radulovacki, M. Role of adenosine in sleep in rats. Rev. Clin. Basic Pharm., 1985, 5(3-4), 327-339.
78. Dunwiddie, T.V.; Masino, S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci., 2001, 24, 31-55.
79. Rainnie, D.G.; Grunze, H.C.; McCarley, R.W.; Greene, R.W. Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal. Science, 1994, 263(5147), 689-692.
80. Porkka-Heiskanen, T.; Strecker, R.E.; Thakkar, M.; Bjorkum, A.A.; Greene, R.W., McCarley, R.W. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science, 1997, 276(5316), 1265-1268.
81. Porkka-Heiskanen, T.; Strecker, R.E.; McCarley, R.W. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience, 2000, 99(3), 507-517.
82. Porkka-Heiskanen, T.; Alanko, L.; Kalinchuk, A.; Stenberg, D. Adenosine and sleep. Sleep Med. Rev., 2002, 6(4), 321-332.
83. Alanko, L.; Heiskanen, S.; Stenberg, D.; Porkka-Heiskanen, T. Adenosine kinase and 5'-nucleotidase activity after prolonged wakefulness in the cortex and the basal forebrain of rat. Neurochem. Int., 2003, 42(6), 449-454.
84. Murillo-Rodriguez, E.; Blanco-Centurion, C.; Gerashchenko, D.; Salin-Pascual, R.J.; Shiromani, P.J. The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience, 2004, 123(2), 361-370.
85. Portas, C.M.; Thakkar, M.; Rainnie, D.G.; Greene, R.W.; McCarley, R.W. Role of adenosine in behavioral state modulation: a microdialysis study in the freely moving cat. Neuroscience, 1997, 79(1), 225-235.
86. Methippara, M.M.; Kumar, S.; Alam, M.N.; Szymusiak, R.; McGinty, D. Effects on sleep of microdialysis of adenosine A1 and A2a receptor analogs into the lateral preoptic area of rats. Am. J. Regul. Integr. Comp. Physiol., 2005, 289(6), R1715-R1723.
87. Stenberg, D.; Litonius, E.; Halldner, L.; Johansson, B.; Fredholm, B.B.; Porkka-Heiskanen, T. Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J. Sleep Res., 2003, 12(4), 283-290.
88. Urade, Y.; Eguchi, N.; Qu, W.M.; Sakata, M.; Huang, Z.L.; Chen, J.F.; Schwarzschild, M.A.; Fink, J.S.; Hayaishi, O. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology, 2003, 61(11 Suppl 6), S94-S96.
89. Basheer, R.; Halldner, L.; Alanko, L.; McCarley, R.W.; Fredholm, B.B.; Porkka-Heiskanen, T. Opposite changes in adenosine A1 and A2A receptor mRNA in the rat following sleep deprivation. Neuroreport, 2001, 12(8), 1577-1580.
90. Alanko, L.O.; Laitinen, J.T.; Stenberg, D.; Porkka-Heiskanen, T. Adenosine A1 receptor-dependent G-protein activity in the rat brain during prolonged wakefulness. Neuroreport, 2004, 15(13), 2133-2137.
91. Strecker, R.E.; Morairty, S.; Thakkar, M.M.; Porkka-Heiskanen, T.; Basheer, R.; Dauphin, L.J.; Rainnie, D.G.; Portas, C.M.; Greene, R.W.; McCarley, R.W. Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav. Brain Res., 2000, 115(2), 183-204.
92. Blanco-Centurion, C.; Xu, M.; Murillo-Rodriguez, E.; Gerashchenko, D.; Shiromani, A.M.; Salin-Pascual, R.J.; Hof, P.R.; Shiromani, P.J. Adenosine and sleep homeostasis in the Basal forebrain. J. Neurosci., 2006, 26(31), 8092-8100.
93. Pivik, R.T.; Zarcone, V.; Dement, W.C.; Hollister, L.E. Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clin. Pharmacol. Ther., 1972, 13(3), 426-435.
94. Moreton, J.E.; Davis, W.M. Electroencephalographic study of the effects of tetrahydrocannabinols on sleep in the rat. Neuropharmacology, 1973, 12(9), 897-907.
95. Feinberg, I.; Jones, R.; Walker, J.M.; Cavness, C.; March, J. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin. Pharmacol. Ther., 1975, 17(4), 458-466.
96. Feinberg, I.; Jones, R.; Walker, J.; Cavness, C.; Floyd, T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin. Pharmacol. Ther., 1976, 19(6), 782-794.
97. Buonamici, M.; Young, G.A.; Khazan, N. Effects of acute delta 9-THC administration on EEG and EEG power spectra in the rat. Neuropharmacology, 1982, 21(8), 825-829. [
98. Freemon, F.R. The effect of chronically administered delta-9- tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers. Drug Alcohol Depend., 1982, 10(4), 345-353.
99. Nicholson, A.N.; Turner, C.; Stone, B.M.; Robson, P.J. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J. Clin. Psychopharmacol., 2004, 24(3), 305-313.
100. Glass, M.; Dragunow, M.; Faull, R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997, 77(2), 299-318.
101. Mackie, K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol., 2005, 168, 299-325.
102. Howlett, A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol., 2005, 168, 53-79.
103. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949.
104. Bisogno, T.; Berrendero, F.; Ambrosino, G.; Cebeira, M.; Ramos, J.A.; Fernandez-Ruiz, J.J.; Di Marzo, V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun., 1999, 256(2), 377-380.
105. Murillo-Rodriguez, E.; Désarnaud, F.; Prospéro- García, O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci., 2006, 79(1), 30-37.
106. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372(6507), 686-691.
107. Hillard, C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat., 2000, 61(1-2), 3-18.
108. Lovinger, D.M. Endocannabinoid liberation from neurons in transsynaptic signaling. J. Mol. Neurosci., 2007, 33(1), 87-93.
109. Ueda, N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat., 2002, 68-69, 521-534.
110. de Lago, E.; Ligresti, A.; Ortar, G.; Morera, E.; Cabranes, A.; Pryce, G.; Bifulco, M.; Baker, D.; Fernandez-Ruiz, J.; Di Marzo, V. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol., 2004, 484(2-3), 249-257.
111. Fegley, D.; Gaetani, S.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther., 2005, 313(1), 352-358.
112. Santucci, V.; Storme, J.J.; Soubrié, P.; Le Fur, G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci., 1996, 58(6), PL103-PL110.
113. Murillo-Rodríguez, E.; Sánchez-Alavez, M.; Navarro, L.; Martínez-González, D.; Drucker-Colín, R.; Prospéro-García, O. Anandamide modulates sleep and memory in rats. Brain Res., 1998, 812(1-2), 270-274.
114. Murillo-Rodríguez, E.; Cabeza, R.; Méndez-Díaz, M.; Navarro, L.; Prospéro-García, O. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport, 2001, 12(10), 2131-2136.
115. Murillo-Rodriguez, E.; Blanco-Centurion, C.; Sanchez, C.; Piomelli, D.; Shiromani, P.J. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep, 2003, 26(8), 943-947.
116. Murillo-Rodríguez, E. The role of the CB1 receptor in the regulation of sleep. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2008, 32(6), 1420-1427.
117. Moldrich, G.; Wenger, T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides, 2000, 21(11), 1735-1742.
118. Ong, W.Y.; Mackie, K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience, 1999, 92(4), 1177-1191.
119. Jones, B.E. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol. Sci., 2005, 26(11), 578-586.
120. Acquas, E.; Pisanu, A.; Marrocu, P.; Di Chiara, G. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur. J. Pharmacol., 2000, 401(2): 179-185.
121. Verrico, C.D.; Jentsch, J.D.; Dazzi, L.; Roth, R.H. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse, 2003, 48(4), 178-183.
122. Williams, J.A.; Comisarow, J.; Day, J.; Fibiger, H.C.; Reiner, P.B. State-dependent release of acetylcholine in rat thalamus measured by in vivo microdialysis. J. Neurosci., 1994, 14(9), 5236-5242.
123. Kodama, T.; Honda, Y. Acetylcholine and glutamate release during sleep-wakefulness in the pedunculopontine tegmental nucleus and norepinephrine changes regulated by nitric oxide. Psychiatry Clin. Neurosci., 1999, 53(2), 109-111.
124. Fuentealba, P.; Steriade, M. The reticular nucleus revisited: intrinsic and network properties of a thalamic pacemaker. Prog. Neurobiol., 2005, 75(2), 125-141.
125. rd ed.; Kryger, M.H.; Roth T.; Dement, W.B., Eds.; Saunders Company: Philadelphia, 2000, pp. 134-154.
126. Murillo-Rodríguez, E.; Vázquez, E.; Millán-Aldaco, D.; Palomero-Rivero, M.; Drucker-Colin, R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur. J. Pharmacol., 2007, 562(1-2), 82-91.
127. de Lago, E.; Petrosino, S.; Valenti, M.; Morera, E.; Ortega-Gutierrez, S.; Fernandez-Ruiz, J.; Di Marzo, V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem. Pharmacol., 2005, 70(3), 446-452.
128. Murillo-Rodríguez, E.; Millán-Aldaco, D.; Di Marzo, V.; Drucker-Colín, R. The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience, 2008, 157(1), 1-11.
129. Ohno, K.; Sakurai, T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front. Neuroendocrinol., 2008, 29(1), 70-87.
130. García-García, F.; Drucker-Colín, R. Endogenous and exogenous factors on sleep-wake cycle regulation. Prog. Neurobiol., 1999, 58(4), 297-314.
131. Garcia-Garcia, F.; Drucker-Colín, R. In Sleep Factors; Pandi-Perumal, S.R.; Verster, J.C.; Monti, J.M.; Lader, M.; Langer, S.Z., Eds.; Informa Healthcare: Abingdon, UK, 2008; pp. 125-132.